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ogy to analyze cells from the thawed segment (w100 ul) for
CD34+ cell count and percent viability by ﬂow cytometry (7-
AAD exclusion using ISHAGE gating), and colony-forming
units (CFU) using high resolution digital imaging (Albano et
al, ASH 2008). At MSKCC, units were thawed using albumin-
dextran dilution, evaluated for CD34+ cell count & viability
(4-color ﬂow cytometry using modiﬁed ISHAGE gating
(Scaradavou et al, BBMT 2010), & CFU assays.
Results: At NCBP there was a high correlation between the
viable CD34+ cell counts and CFU in pre-cryopreservation
and segment data (Table). In the 68 CBU thawed at MSKCC,
the average decrease in CD34+ cell viability post-thaw
compared to that of the segment was 1.9% (SD:+/-3.9%;
p < 0.001) & ranged -11.0% to +12.0% with the lowest
post-thaw CD34+ cell viability being 82% (Figure 1).
Moreover, despite potential differences in laboratories
and ﬂow cytometric gating, the number of viable CD34+
cells in the unit post-thaw correlated with both the
pre-cryopreservation viable CD34+ counts and the results
of the segment (Table). The median viable CD34+ cell
recovery (ratio of post-thaw to segment viable CD34+
counts) was 128% (SD:+/-43.2). In contrast, however, post-
thaw CFU had weak correlation with pre-cryopreservation
and segment values (Table).
Conclusions: Testing of CBU segments can accurately
measure the potency of the frozen CB products, & segment
calculations may even underestimate the post-thaw CBU
CD34+ cell content. Although the decrease in post-thaw CBUFigure 1. Comparison of segment and post-thaw CBU CD34+ cell viability.CD34+ cell viability was statistically signiﬁcant, this
difference was too low to be clinically relevant. The poor
correlation between segment and post-thaw CFU likely
reﬂects signiﬁcant inter-laboratory assay variability.
These ﬁndings indicate that the processing procedures,
cryopreservation technology and thaw/dilution methodol-
ogy generate high quality units and that testing segment
CD34+ cell counts and the percentage of viable cells can
predict the post-thaw potency. Whether these ﬁndings can
be generalized to other CB banks and transplant centers
requires further investigation.HISTOCOMPATIBILITY/ALTERNATIVE STEM CELL SOURCES
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Background: Previous reports from single centers suggested
that MICA polymorphism and donor/recipient MICA mis-
matches are associatedwith chronic graft versus host disease
(GVHD) and acute GVHD (respectively) after unrelated donor
HSCT. MICA is both a transplantation antigen and a ligand
recognized by the activating receptor NKG2D expressed by
NK, NKT, CD8+ and TCRgd+ Tcells. Allelic variants ofMICAdue
to a single amino acid substitution at position 129 result in
signiﬁcant differences in NKG2D binding. MICA alleles with a
methionine (M) or valine (V) have been classiﬁed as having
strong or weak binding afﬁnity for NKG2D, respectively.
Methods:We studied the association ofMICA polymorphism
(MICA-129) and MICA mismatches with unrelated donor
HSCT with 10/10 HLA match (n¼552 pairs) or 9/10 (HLA-B
mismatch only, n¼161 pairs), reported to the CIBMTR be-
tween 2000 and 2011. Included were adult patients who had
undergone a ﬁrst unrelated bonemarrow or peripheral blood
HSCT for ALL, AML, or MDS. Pre-transplant samples were
obtained from the NMDP Research Repository. MICA typing
was performed using rSSOP (One Lambda Thermo Fisher,
Canoga Park, CA). Study outcomes included overall survival,
disease-free survival, treatment-related mortality, relapse,
acute graft vs. host disease (GVHD), chronic GVHD, and
engraftment. Variables considered in multivariate analyses
included patient, disease and transplant characteristics. A p
value < 0.01 for the main effect was considered signiﬁcant.
Results: Of the recipients 101 wereMICA-129MM (14%), 363
MV (52%), and 239 VV (34%). Of the donors 106 were MICA-
129 MM (15%), 375 MV (53%), and 229 VV (32%). 27% of the
pairs were MICA mismatched, 9 pairs had double (one 10/10
and eight 9/10) and 182 had single mismatches (83 10/10 and
99 9/10). At 0.01 signiﬁcance level, there was no association
between any outcome and MICA mismatch or MICA-129
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of signiﬁcantly higher relapse in association with MICA
mismatches in 10/10 patients (HR 1.7, 95% CI 1.2-2.4, p¼
0.003) but not in 9/10 patients. There was a suggestion that
MICA mismatches were associated with a higher risk of
aGVHD grades II-IV (HR 1.4, 95% CI 1.1-1.9, p¼ 0.013) but not
grades III-IV and with higher risk of cGVHD (HR 1.8, 95% CI:
1.0-3.1, p value 0.04). There were no signiﬁcant interactions
between MICA mismatches and HLA matching (9/10 vs. 10/
10). There was also a suggestion of an association between
donor MICA-129 non-VV genotypes and slower platelet
engraftment with HR 1.4 (95% CI 1.109-1.985, p¼ 0.02).
Conclusions: In this cohort neither MICA-129 poly-
morphism nor MICA mismatches were associated with HSCT
outcomes at a level that reached the predetermined level of
statistical signiﬁcance. This registry analysis in patients with
ALL, AML and MDS was discordant with prior reports of
single center studies of patients with mixed diagnoses.Figure.188
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Background: Double cord blood transplantation (dCBT) is an
important strategy to overcome dose limitation of single CBT
and extend its availability to a broader range of patients (pts).
The dominance of one of the two CB units occurs as early as
12 days after dCBT, and by day 21, over 80% of transplanted
pts have single unit dominance maintaining long-term he-
matopoiesis. However, outcomes of pts who do not achieve
unit dominance, but rather persistence of both CB units after
dCBT is not known.
Methods: We retrospectively analyzed 105 pts with hema-
tological malignancies who engrafted after dCBT between
2003 through 2014 and investigated the presence of donor T
cell chimerism (TCC) of at least 10% from each CB unit at day
100 +/- 30 after transplant (dTCC). Only pts with progression
free survival at day 100 were evaluable.
Results: Of 105 pts, 10 (9.5%) had dTCC. Median age was 43
(range; 1e73). AMLwas themost commondiagnosis in 57.1% of
the pts followed by ALL in 21.9. Disease status was complete
remission (CR) in 67.6% and active disease in 32.4% of the pts.
Conditioningwasmyeloablative in 73.3% and reduced intensity
in 26.7% due to older age and/or frailty. Immunosuppressive
therapy included mycophenolate mofetil with tacrolimus, and
all pts received anti-thymocyte globulin as a part of the con-
ditioning regimen. Per protocol priority over the years, 72.4% of
the pts had ex-vivo expansion of one of the CB units in
mesenchymal stem cell co-culture. Final median dose of CD34+
and total nucleated cells infused were 0.36x106/kg (0.12-5.35)
and 0.51x107/kg (0.3-1.29) respectively.
Patient, disease and graft characteristics were very similar
between dTCC and single donor TCC (sTCC) pts. However,
compared to sTCC, dTCC pts had better 4/6 HLA matching
between 2 CB units (66.3% vs. 90%, p¼0.1) and less manip-
ulation of one of the CB units with expansion (74.7% vs. 50%,
p¼0.1).Median follow-up was 44.7 months (mo). Transplant out-
comes were similar between dTCC and sTCC pts with 3-year
(yr) overall survival and progression free survival of 40% vs.
41.4% and 40% vs. 32.3% respectively. Incidence of progression
was similar between dTCC and sTCC groups (28.9% vs. 27.6%).
Of 10 pts with dTCC, 3 died within 6 mo after dCBT without
repeat TCC and they were not evaluable for long-term assess-
ment. Among others, 1 pt had autologous recovery with pro-
gression after 6 mo of dCBT. Unit dominance with 100% TCC
was observed in 4 pts within 4 to 20 mo after dCBT; 1 of those
pts progressed 5 mo after unit dominance was established and
another pt died of fungal infection at 15 mo. However, 2 AML
pts showed long-term dTCC with units contributing 58%/42%
and 84%/16% at last evaluation, 4 and 3.2 years after dCBT. They
both remain in CR and free of progression.
Conclusion: The unique situation of TCC from both CB units
around day 100 is not associated with worse transplant
outcomes in pts receiving dCBT. These provocative results
need to be conﬁrmed in larger studies.189
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Background: Availability of suitably HLA-matched unrelated
donors (URD) is a major barrier to allogeneic transplantation
especially in minorities & patients with acute leukemia &
lymphoma requiring urgent transplant. The extent that cord
blood (CB) extends transplant access, however, is not estab-
lished. Moreover, the contribution of the domestic U.S. &
international CB inventories to minority patients is an
important factor in public CB Bank funding considerations.
Methods:We prospectively analyzed the availability of 7-8/8
HLA-matched URDs or 4-6/6 HLA-A,-B antigen, -DRB1 allele
matched CB units in patients with hematologic malignancies
